Kidney Research and Clinical Practice · 2018 · 23 citations · 22 references
MedicineImmunologyNephrologyAutoimmunityImmunopathologyRenal PathologyAutoantibodiesChronic Kidney DiseaseGlomerular DiseasesRenal DiseaseRenal Function TestsRenal ImmunopathologyAutoantigen IdentificationPhospholipase A2 PathwayPhospholipase A2 Receptor AutoantibodiesPrognostic Marker AssessmentPrognostic Marker EvaluationProtein-to-creatinine RatioRenal Biopsy FindingsUrine Protein Testing
BACKGROUND: Phospholipase A2 receptor (PLA2R) has been identified as a major autoantigen in primary membranous nephropathy (MN). We evaluated the association between anti-PLA2R antibodies and clinical outcome in Korean patients with primary MN. METHODS: A total of 66 patients with biopsy-proven MN were included. Serum level of anti-PLA2R antibodies was measured by enzyme-linked immunosorbent assay. Biochemical parameters were estimated initially and at follow-up. RESULTS: < 0.001). Multivariate analysis demonstrated that anti-PLA2R antibodies are an independent risk factor for developing chronic kidney disease stage ≥ 3 and for not reaching spontaneous remission. CONCLUSION: Detection of anti-PLA2R antibodies at diagnosis in patients with primary MN can predict prognosis and guide treatment decisions.
22
Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy
Arrigo Schieppati, Lidia Mosconi, Annalisa Perna et al. · New England Journal of Medicine · 1993 · 436 citations · Full text